18:09 , May 11, 2018 |  BC Week In Review  |  Company News

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced an Ebola virus outbreak in the...
23:04 , May 9, 2018 |  BC Extra  |  Politics & Policy

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced Tuesday an Ebola virus outbreak in...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

MVA-BN Filo: Phase III started

Johnson & Johnson began the open-label, Sierra Leonean Phase III EBOVAC-Salone trial to evaluate 0.5 mL intramuscular Ad26.ZEBOV followed by 0.5 mL intramuscular MVA-BN Filo 2 months later in about 440 healthy volunteers. The...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Ad26: Phase III started

Johnson & Johnson began the open-label, Sierra Leonean Phase III EBOVAC-Salone trial to evaluate 0.5 mL intramuscular Ad26.ZEBOV followed by 0.5 mL intramuscular MVA-BN Filo 2 months later in about 440 healthy volunteers. The...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Ad26: Phase II started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the Oxford Vaccines Group of the University of Oxford (Oxford, U.K.) began a double-blind, U.K. and French Phase II trial to evaluate the company’s MVA-BN Filo...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

MVA-BN Filo: Phase II started

Bavarian Nordic said the Oxford Vaccines Group of the University of Oxford (Oxford, U.K.) began a double-blind, U.K. and French Phase II trial to evaluate the company’s MVA-BN Filo vaccine and the Ad26.ZEBOV...